Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.67
ABBV's Cash to Debt is ranked higher than
54% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ABBV: 0.67 )
ABBV' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.67

Equity to Asset 0.15
ABBV's Equity to Asset is ranked higher than
50% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ABBV: 0.15 )
ABBV' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.61
Current: 0.15

-0.01
0.61
Interest Coverage 18.94
ABBV's Interest Coverage is ranked higher than
55% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ABBV: 18.94 )
ABBV' s 10-Year Interest Coverage Range
Min: 18.94   Max: 9999.99
Current: 18.94

18.94
9999.99
F-Score: 6
Z-Score: 3.67
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.14
ABBV's Operating margin (%) is ranked higher than
95% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ABBV: 30.14 )
ABBV' s 10-Year Operating margin (%) Range
Min: 20.75   Max: 34.7
Current: 30.14

20.75
34.7
Net-margin (%) 21.97
ABBV's Net-margin (%) is ranked higher than
93% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ABBV: 21.97 )
ABBV' s 10-Year Net-margin (%) Range
Min: 19.68   Max: 32.62
Current: 21.97

19.68
32.62
ROE (%) 91.90
ABBV's ROE (%) is ranked higher than
99% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ABBV: 91.90 )
ABBV' s 10-Year ROE (%) Range
Min: 28.77   Max: 91.9
Current: 91.9

28.77
91.9
ROA (%) 14.14
ABBV's ROA (%) is ranked higher than
96% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ABBV: 14.14 )
ABBV' s 10-Year ROA (%) Range
Min: 14.14   Max: 19.53
Current: 14.14

14.14
19.53
ROC (Joel Greenblatt) (%) 148.94
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ABBV: 148.94 )
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 122.13   Max: 149.5
Current: 148.94

122.13
149.5
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ABBV Guru Trades in Q2 2013

Jeremy Grantham 21,300 sh (New)
George Soros 1,008,752 sh (+203.98%)
Joel Greenblatt 101,753 sh (+171.43%)
Ken Fisher 1,147,117 sh (+156.69%)
Bill Frels 279,466 sh (+2.92%)
Murray Stahl 33,687 sh (+0.18%)
Westport Asset Management 180,000 sh (unchged)
John Hussman 403,250 sh (unchged)
Robert Bruce 234,300 sh (unchged)
George Soros 165,000 sh (unchged)
Jeff Auxier 80,440 sh (unchged)
Daniel Loeb Sold Out
John Buckingham Sold Out
Manning & Napier Advisors, Inc 226,194 sh (-0.06%)
PRIMECAP Management 5,979,247 sh (-0.21%)
Tom Russo 87,127 sh (-1.27%)
Dodge & Cox 37,265 sh (-1.58%)
Pioneer Investments 2,062,351 sh (-8.15%)
Mario Gabelli 10,080 sh (-36.12%)
Vanguard Health Care Fund 8,459,700 sh (-40.22%)
Steven Cohen 511,871 sh (-55.59%)
Paul Tudor Jones 350,000 sh (-56.25%)
Jim Simons 540,300 sh (-77.75%)
» More
Q3 2013

ABBV Guru Trades in Q3 2013

Jeremy Grantham 519,190 sh (+2337.51%)
Jim Simons 1,991,500 sh (+268.59%)
Joel Greenblatt 141,954 sh (+39.51%)
Paul Tudor Jones 353,100 sh (+0.89%)
Manning & Napier Advisors, Inc 227,657 sh (+0.65%)
Murray Stahl 33,840 sh (+0.45%)
Vanguard Health Care Fund 8,459,700 sh (unchged)
Mario Gabelli 10,080 sh (unchged)
Jeff Auxier 80,440 sh (unchged)
Robert Bruce 234,300 sh (unchged)
George Soros 165,000 sh (unchged)
John Hussman 403,250 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Dodge & Cox 37,165 sh (-0.27%)
Tom Russo 86,777 sh (-0.4%)
George Soros 1,000,000 sh (-0.87%)
Pioneer Investments 2,039,509 sh (-1.11%)
PRIMECAP Management 5,892,547 sh (-1.45%)
Bill Frels 268,187 sh (-4.04%)
Ken Fisher 1,065,932 sh (-7.08%)
Steven Cohen 178,199 sh (-65.19%)
» More
Q4 2013

ABBV Guru Trades in Q4 2013

David Dreman 4,572 sh (New)
Steven Cohen 1,088,256 sh (+510.7%)
George Soros 1,147,609 sh (+14.76%)
Ken Fisher 1,140,946 sh (+7.04%)
Bill Frels 279,694 sh (+4.29%)
Murray Stahl 35,285 sh (+4.27%)
Mario Gabelli 10,080 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Tom Russo 86,777 sh (unchged)
Pioneer Investments 2,037,103 sh (-0.12%)
PRIMECAP Management 5,850,670 sh (-0.71%)
Robert Bruce 231,300 sh (-1.28%)
Dodge & Cox 36,649 sh (-1.39%)
Jeff Auxier 78,440 sh (-2.49%)
Jim Simons 1,809,600 sh (-9.13%)
John Hussman 303,250 sh (-24.8%)
Joel Greenblatt 103,981 sh (-26.75%)
Manning & Napier Advisors, Inc 149,065 sh (-34.52%)
Jeremy Grantham 284,091 sh (-45.28%)
Paul Tudor Jones 76,100 sh (-78.45%)
Vanguard Health Care Fund 1,739,600 sh (-79.44%)
» More
Q1 2014

ABBV Guru Trades in Q1 2014

Manning & Napier Advisors, Inc 146,077 sh (-2%)
Ken Fisher 627,139 sh (-45.03%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-12-31 Reduce -79.44%1.03%$44.52 - $54.32 $ 49.320%1739600
John Hussman 2013-12-31 Reduce -24.8%0.25%$44.52 - $54.32 $ 49.320%303250
Joel Greenblatt 2013-12-31 Reduce -26.75%0.06%$44.52 - $54.32 $ 49.320%103981
David Dreman 2013-12-31 New Buy0.02%$44.52 - $54.32 $ 49.320%4572
Joel Greenblatt 2013-09-30 Add 39.51%0.06%$42.21 - $47.92 $ 49.3211%141954
Daniel Loeb 2013-06-30 Sold Out 2.3%$40.57 - $47.17 $ 49.3213%0
Vanguard Health Care Fund 2013-06-30 Reduce -40.22%0.93%$40.57 - $47.17 $ 49.3213%8459700
George Soros 2013-06-30 Add 203.98%0.3%$40.57 - $47.17 $ 49.3213%1008752
Joel Greenblatt 2013-06-30 Add 171.43%0.11%$40.57 - $47.17 $ 49.3213%101753
Mario Gabelli 2013-06-30 Reduce -36.12%$40.57 - $47.17 $ 49.3213%10080
Vanguard Health Care Fund 2013-03-31 Add 760.24%2.03%$33.71 - $40.78 $ 49.3233%14151000
Daniel Loeb 2013-03-31 Add 609.13%1.98%$33.71 - $40.78 $ 49.3233%2950000
John Hussman 2013-03-31 New Buy0.6%$33.71 - $40.78 $ 49.3233%403250
PRIMECAP Management 2013-03-31 New Buy0.36%$33.71 - $40.78 $ 49.3233%5991647
George Soros 2013-03-31 New Buy0.16%$33.71 - $40.78 $ 49.3233%331852
Joel Greenblatt 2013-03-31 New Buy0.08%$33.71 - $40.78 $ 49.3233%37488
Mario Gabelli 2013-03-31 New Buy$33.71 - $40.78 $ 49.3233%15780
Dodge & Cox 2013-03-31 New Buy$33.71 - $40.78 $ 49.3233%37865
Mason Hawkins 2013-03-31 Sold Out $33.71 - $40.78 $ 49.3233%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on AbbVie Inc

Lountzis Asset Management Comments on Abbvie - Mar 21, 2014

ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about AbbVie Inc

Lountzis Asset Management Comments on Abbvie
ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion. Read more...
Daniel Loeb's Top Three Increases of the First Quarter
Billionaire Daniel Loeb of Third Point LLC has a portfolio consisting of 40 stocks, 12 of those being new buys, valued at $5.3 billion. Loeb is well known in the financial world for writing public letters in which he expresses disapproval of the performance and conduct of other financial executives. In 2012 the guru reported a return of 21.2%, an excess gain of 5.8% over the S&P 500’s return. Read more...
Mason Hawkins Gives Mickey Mouse the Boot, First Quarter Sells in Review
Demonstrating once again that emotion can never get in the way of investing decisions, Guru Mason Hawkins of Southeastern Asset Management determined in the first quarter of 2013 that, as the Mickey Mouse Club once sang, “Now it’s time to say goodbye.” Hawkins let go of Mickey Mouse and other timeless icons of entertainment when he sold out his long-held stake in Walt Disney Co., as well as seven more companies. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 19.20
ABBV's P/E(ttm) is ranked higher than
84% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. ABBV: 19.20 )
ABBV' s 10-Year P/E(ttm) Range
Min: 9.86   Max: 20.87
Current: 19.2

9.86
20.87
P/B 17.40
ABBV's P/B is ranked lower than
71% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ABBV: 17.40 )
ABBV' s 10-Year P/B Range
Min: 16.48   Max: 25.22
Current: 17.4

16.48
25.22
P/S 4.20
ABBV's P/S is ranked higher than
78% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ABBV: 4.20 )
ABBV' s 10-Year P/S Range
Min: 2.83   Max: 4.57
Current: 4.2

2.83
4.57
PFCF 13.70
ABBV's PFCF is ranked higher than
87% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. ABBV: 13.70 )
ABBV' s 10-Year PFCF Range
Min: 8.64   Max: 14.89
Current: 13.7

8.64
14.89
EV-to-EBIT 14.70
ABBV's EV-to-EBIT is ranked higher than
71% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ABBV: 14.70 )
ABBV' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 16
Current: 14.7

10.3
16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.40
ABBV's Dividend Yield is ranked higher than
91% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. ABBV: 3.40 )
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 3.44
Current: 3.4

0.85
3.44
Dividend Payout 0.59
ABBV's Dividend Payout is ranked higher than
52% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. ABBV: 0.59 )
ABBV' s 10-Year Dividend Payout Range
Min: 0.63   Max: 0.63
Current: 0.59

Yield on cost (5-Year) 3.30
ABBV's Yield on cost (5-Year) is ranked higher than
89% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. ABBV: 3.30 )
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.44
Current: 3.3

0.85
3.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.12
ABBV's Price/Median PS Value is ranked higher than
65% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ABBV: 1.12 )
ABBV' s 10-Year Price/Median PS Value Range
Min: 0.76   Max: 1.18
Current: 1.12

0.76
1.18
Earnings Yield (Greenblatt) 6.80
ABBV's Earnings Yield (Greenblatt) is ranked higher than
74% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ABBV: 6.80 )
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.2   Max: 9.7
Current: 6.8

6.2
9.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment—pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide